| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/10/2009 | EP2067488A1 Albumin fusion proteins |
| 06/10/2009 | EP2067482A1 Agent for preventing development of reflex sympathetic dystrophy after stroke |
| 06/10/2009 | EP2066791A2 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| 06/10/2009 | EP2066680A1 Triphenylphosphonium thionitrite nitric oxide donors |
| 06/10/2009 | EP1983978A4 Novel application of topical anesthetics for modulation of neurogenic tremor |
| 06/10/2009 | EP1383869B1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
| 06/10/2009 | CN101450934A Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 06/10/2009 | CN100497388C Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof |
| 06/10/2009 | CN100497323C New heterocyclic oxime compounds, preparing process and medical composition thereof |
| 06/09/2009 | US7544357 Administering an interferon antagonist and a FMS-like tyrosine kinase 3 ("Flt3") ligand antagonist, such as an anti-IFN-alpha antibody; in vitro assay for determining risk for developing an autoimmune disease |
| 06/09/2009 | CA2269083C Novel fgf homologs |
| 06/04/2009 | WO2009069736A1 Nitrogenated compound |
| 06/04/2009 | WO2009068689A2 Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders |
| 06/04/2009 | US20090143480 for improving feed efficiency and muscle-to-fat ratio in animals; side effect reduction |
| 06/04/2009 | US20090143376 Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators |
| 06/04/2009 | US20090142841 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| 06/04/2009 | US20090142831 Placental stem cells |
| 06/04/2009 | CA2707117A1 Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders |
| 06/03/2009 | EP2065401A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065400A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2063880A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 06/03/2009 | EP2063877A2 Drugs comprising at inhibitor of class i alpha mannosidase for the treatment of sarcoglycanopathies |
| 06/03/2009 | CN101444509A Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 06/03/2009 | CN100494182C Regulatory factor of tumor necrosis alpha factor |
| 06/03/2009 | CN100493617C Recombinant adeno-associated virus for prevention and cure of I-type diabetes and use thereof |
| 06/02/2009 | US7541376 3-(3-Fluoro-phenyl)-6-methoxy-1H-indazole-5-carboxylic acid(furan-2-ylmethyl)-amide; 3-Benzo[b]thiophen-2-yl-4-methoxy-1H-indazole-5-carboxylic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; Jun amino-terminal kinase (JNK) inhibitor; immunologic disease, inflammatory and neurodegenerative diseases |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541154 GASP1: a follistatin domain containing protein |
| 06/02/2009 | CA2394606C New modulators of dopamine neurotransmission |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 05/29/2009 | CA2645441A1 Compositions of tolperisone |
| 05/28/2009 | WO2009066457A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/28/2009 | WO2009065854A1 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors |
| 05/28/2009 | US20090137629 Sigma receptor binding agent containing indanone derivative |
| 05/28/2009 | US20090137575 Fused Tetracyclic mGluR1 Antagonists as Therapeutic Agents |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090136970 Nogo receptor homologues and their use |
| 05/28/2009 | US20090136561 Non-peptidyl agents with pHSP20-like activity, and uses thereof |
| 05/28/2009 | US20090136481 Use of Myostatin (GDF-8) Antagonists for Treatment of Sarcopenia (Age-Related Muscle-Wasting) |
| 05/28/2009 | DE102007056424A1 Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion A pharmaceutical composition containing an oil / water emulsion |
| 05/28/2009 | CA2705965A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/27/2009 | EP2062879A1 Heterocyclic inhibitors of p38 |
| 05/27/2009 | EP2062583A2 Therapeutic applications of pro-apoptotic benzodiazepines |
| 05/27/2009 | EP2062577A1 Oleanolic acid derivatives as NO production inhibitors |
| 05/27/2009 | EP2061473A1 Increasing atp availability by inhibition of creatine kinase (ck) leakage resulting from high-intensity exercise |
| 05/27/2009 | EP1351672B1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 05/27/2009 | EP1292678B1 G-protein coupled receptors |
| 05/27/2009 | CN101443000A Xanthone derivative for the treatment of muscular disorders |
| 05/27/2009 | CN101440124A Methods for preventing mitochondrial permeability transition |
| 05/27/2009 | CN100491374C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors |
| 05/27/2009 | CN100491371C Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) |
| 05/27/2009 | CN100490902C Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538089 Anti-inflammatory compounds and uses thereof |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2337041C Aminomethylcarboxylic acid derivatives |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009062683A1 C-19 steroids for therapeutic uses |
| 05/22/2009 | WO2009019505A3 Drug combinations for the treatment of duchenne muscular dystrophy |
| 05/21/2009 | US20090131456 Caspase inhibitors and uses thereof |
| 05/21/2009 | US20090131421 Compounds for proteasome enzyme inhibition |
| 05/21/2009 | US20090131387 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism |
| 05/21/2009 | US20090131347 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/20/2009 | EP2060300A1 C-19 steroids for therapeutic uses |
| 05/20/2009 | EP2059500A2 Inhibitors of zinc proteases thioaryl substituted and their use |
| 05/19/2009 | US7534863 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins |
| 05/19/2009 | US7534800 pyrrolo[2,3-b]pyridine derivatives; treatment of neurodegenerative disorders related to apoptosis and/or inflammation; compound prepared by condensation, halogenation, hydrogenation, using silan protected drivatives |
| 05/19/2009 | US7534790 Aminocyclohexyl ether compounds such as trans-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane; arrhythmia, analgesia and local anesthesia |
| 05/19/2009 | US7534439 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 05/19/2009 | CA2345024C Modified tgf-.beta. superfamily proteins |
| 05/19/2009 | CA2336634C Antiviral macrocyclic compounds |
| 05/14/2009 | WO2008041236A3 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 05/14/2009 | US20090124793 Corticotropin releasing factor 2 receptor agonists |
| 05/14/2009 | US20090124674 Method for treating congestive heart failure |
| 05/14/2009 | US20090124673 Method for treating diabetic nephropathy |
| 05/14/2009 | US20090124590 Pharmaceutical composition |
| 05/14/2009 | US20090124589 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism |
| 05/13/2009 | EP2058317A1 Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| 05/13/2009 | EP2056682A1 Novel use |
| 05/12/2009 | US7531625 Nucleotide sequences coding neuronal outgrowth and stability protein for use in treating ovarian, renal, neurological, cell proliferative and cardiovascular disorders |
| 05/12/2009 | US7531536 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 05/12/2009 | US7531183 Biologically active hemagglutinin from type A Clostridium botulinum and methods of use |
| 05/12/2009 | CA2590293C Use of the neurotoxic component of botulinum to treat a spastic muscle |
| 05/12/2009 | CA2356080C Improved formulation for transportation of corticosteroid through pores of a barrier |
| 05/07/2009 | WO2009057086A1 Novel r,r'-atracurium salts |
| 05/07/2009 | US20090118475 Clostridial Neurotoxin Compositions and Modified Clostridial Neurotoxins |
| 05/07/2009 | US20090118330 Diurea derivatives |
| 05/07/2009 | US20090118252 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism |
| 05/07/2009 | US20090118251 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism |
| 05/07/2009 | US20090118250 Pharmaceutical composition |
| 05/07/2009 | US20090118182 Fibroblast Growth Factor-Like Polypeptides |
| 05/07/2009 | US20090117193 Compositions Comprising an Active Agent |
| 05/07/2009 | US20090117133 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS |